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A randomized phase III study of carﬁlzomib vs low-dose
corticosteroids with optional cyclophosphamide in relapsed
and refractory multiple myeloma (FOCUS)
R Hájek1, T Masszi2, MT Petrucci3, A Palumbo4, L Rosiñol5, A Nagler6, KL Yong7, A Oriol8, J Minarik9, L Pour1, MA Dimopoulos10,
V Maisnar11, D Rossi12, H Kasparu13, J Van Droogenbroeck14, DB Yehuda15, I Hardan16, M Jenner17, M Calbecka18, M Dávid19,
J de la Rubia20, J Drach21, Z Gasztonyi22, S Górnik23, X Leleu24, M Munder25, M Ofﬁdani26, N Zojer27, K Rajangam28, Y-L Chang28,
JF San-Miguel29 and H Ludwig30
This randomized, phase III, open-label, multicenter study compared carﬁlzomib monotherapy against low-dose corticosteroids
and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma
patients were randomized (1:1) to receive carﬁlzomib (10-min intravenous infusion; 20 mg/m2 on days 1 and 2 of cycle 1; 27 mg/m2
thereafter) or a control regimen of low-dose corticosteroids (84 mg of dexamethasone or equivalent corticosteroid) with optional
cyclophosphamide (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred and ﬁfteen patients
were randomized to carﬁlzomib (n= 157) or control (n= 158). Both groups had a median of ﬁve prior regimens. In the control group,
95% of patients received cyclophosphamide. Median OS was 10.2 (95% conﬁdence interval (CI) 8.4–14.4) vs 10.0 months (95%
CI 7.7–12.0) with carﬁlzomib vs control (hazard ratio = 0.975; 95% CI 0.760–1.249; P= 0.4172). Progression-free survival was similar
between groups; overall response rate was higher with carﬁlzomib (19.1 vs 11.4%). The most common grade ⩾ 3 adverse events
were anemia (25.5 vs 30.7%), thrombocytopenia (24.2 vs 22.2%) and neutropenia (7.6 vs 12.4%) with carﬁlzomib vs control. Median
OS for single-agent carﬁlzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients.
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INTRODUCTION
Therapeutic options are limited for patients with relapsed and
refractory multiple myeloma (RRMM). Although treatment may
induce remission, patients experience multiple relapses.1 Each
subsequent remission becomes increasingly shorter in duration,
and patients ultimately die from complications of the disease.2–5
Historically, patients have survival duration of o12 months and
response rates of approximately 15% at fourth relapse.3,4,6,7
Treatment options for patients refractory to both the protea-
some inhibitor bortezomib and an immunomodulatory agent are
especially limited. In a retrospective study of 286 patients who
were refractory to both bortezomib and immunomodulatory
agents, median overall survival (OS) was approximately 9 months.3
Carﬁlzomib and pomalidomide are two treatments that are
currently approved in the United States for patients with RRMM
who have received prior bortezomib and either thalidomide or
lenalidomide.8,9 The approval of carﬁlzomib, a proteasome
inhibitor that binds selectively and irreversibly to its target, was
based on the overall response rate (ORR) from a phase II study in
heavily pretreated patients.10 That study and other phase II
studies further established the safety proﬁle of single-agent
carﬁlzomib.10–15
Here we present the results of the randomized phase III
study PX-171-011 (FOCUS), which investigated single-agent
carﬁlzomib vs low-dose corticosteroids with optional cyclopho-
sphamide in patients with advanced RRMM. In the absence
of an established standard of care, the control regimen was
chosen on the basis of discussions with multiple myeloma
(MM) experts and results from several small studies (20–42
patients) that showed disease response and symptom abate-
ment using this combination as salvage therapy in advanced
MM.16–18
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METHODS
Participants
FOCUS was a randomized, open-label, phase III study. Participants
were recruited from 77 study sites in Europe, Australia, New Zealand and
South Korea.
Eligible patients (age ⩾ 18 years) with Eastern Cooperative Oncology
Group performance status 0–2 had received at least three prior treatments
for MM, including bortezomib, lenalidomide or thalidomide, an alkylating
agent, corticosteroids and anthracycline (for patients enrolled prior to
Amendment 2), and were refractory to their most recent therapy. Patients
with some impairment of bone marrow and organ function
were eligible, including those with reduced platelet counts (430 000/μl)
and with creatinine clearance (CrCl) ⩾ 15 ml/min.
Exclusion criteria included the presence of Waldenström macroglobuline-
mia, immunoglobulin M myeloma, plasma cell leukemia, other malignancy in
the previous 3 years, POEMS syndrome, prior carﬁlzomib, major surgery
within 21 days prior to randomization, New York Heart Association class III/IV
congestive heart failure, myocardial infarction in the previous 3 months,
HIV seropositivity, active hepatitis, and signiﬁcant neuropathy (grade 3 or 4,
or grade 2 with pain).
The protocol was approved by each study center’s Institutional Review
Board or Independent Ethics Committee. The study was conducted in
accordance with the Declaration of Helsinki and was consistent with the
Guidelines for Good Clinical Practice and all applicable regulatory
guidelines. All patients provided written informed consent.
Procedures
Patients were randomized 1:1 using an interactive Web response system
to receive either carﬁlzomib or control (deﬁned as corticosteroids with
optional cyclophosphamide) and were stratiﬁed by number of prior
therapies (3 vs 4 vs ⩾ 5) and geographic region (Europe vs non-Europe).
The randomization schedule was prepared using a blocked randomization
scheme (block size of 4). Study investigators and patients were not blinded
to treatment. The sponsor’s study team did not evaluate unblinded
aggregate study results until completion of the study. Unmasked safety
data were evaluated by an independent data-monitoring committee via an
independent external statistical analysis group on a regular basis.
Patients were treated in 28-day cycles according to the following
schedule: during cycles 1–9, patients in the carﬁlzomib group received
carﬁlzomib at a starting dose of 20 mg/m2 administered intravenously over
Figure 1. Random assignment and follow-up.
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10 min on days 1 and 2 of cycle 1, which was escalated to a target dose of
27 mg/m2 on days 8, 9, 15 and 16 of cycle 1 and continued on days 1, 2, 8,
9, 15 and 16 of cycles 2–9. During cycles 10 and beyond, carﬁlzomib was
administered at 27 mg/m2 on days 1, 2, 15 and 16; treatment on days 8
and 9 was optional per the investigator’s discretion. During cycle 1,
patients received oral (PO) and intravenous (IV) hydration (before and after
dose), dexamethasone 4 mg (before dose; PO or IV), and ciproﬂoxacin
(500 mg PO, once daily (QD)). For patients with a history of herpes zoster,
valacyclovir or an equivalent antiviral medication was required.
For patients randomized to receive control, treatment consisted of a
corticosteroid (prednisone 30 mg PO every other day, dexamethasone
6 mg PO every other day, or other equivalent corticosteroid (not to exceed
84 mg dexamethasone or equivalent per 28-day cycle)). Patients could
receive optional cyclophosphamide 50 mg PO, QD (1400 mg maximum per
cycle) per the investigator’s discretion.
Treatment was continued until conﬁrmed progressive disease, unac-
ceptable toxicity or consent withdrawal. Dose reductions of carﬁlzomib
to 20, 15 or 11 mg/m2 were permitted, as necessary, to manage toxicity.
Objectives
The primary endpoint of the study was OS, which was deﬁned as the time
from randomization to death from any cause. Secondary endpoints
included progression-free survival (PFS), which was deﬁned as the time
from randomization to conﬁrmed progressive disease or death from any
cause; ORR, which was deﬁned as the proportion of patients who achieved
partial response or better according to the International Myeloma Working
Group criteria;19 duration of response, which was deﬁned as the time from
the start date of achieving a partial response or better until conﬁrmed
progressive disease or death from any cause; clinical beneﬁt rate, which
was deﬁned as ORR with the addition of minimal response according
to European Group for Blood and Marrow Transplant criteria;20 disease
control rate, which was deﬁned as clinical beneﬁt rate plus stable disease
lasting ⩾ 8 weeks; and safety.
Assessments
Patients were evaluated for disease response and progression (as determined
by investigator assessment) on day 1 of each cycle. Treatment-emergent
adverse events were assessed at each visit according to the National
Cancer Institute Common Terminology Criteria for Adverse Events v4.0 and
were coded using the Medical Dictionary for Regulatory Activities v15.1.
Treatment-emergent adverse events were deﬁned as adverse events (AEs)
that started on or after the ﬁrst administration of study treatment and within
30 days of the last administration of study treatment. All available laboratory
data were reported according to International System of Units. Results of
selected laboratory analyses were summarized descriptively and graded
according to National Cancer Institute Common Terminology Criteria for
Adverse Events, v4.0. An independent data-monitoring committee reviewed
the study data on an ongoing basis. A preplanned interim efﬁcacy analysis
took place after approximately 75% of the OS events had occurred, and the
independent data-monitoring committee recommended that the study be
continued until enough events had occurred to perform the ﬁnal analysis.
Statistical analyses
The study had a planned enrollment of 302 patients; it was estimated that
253 OS events would provide 80% power to detect a 30% reduction in the
risk of death (that is, hazard ratio (HR) of 0.70) with an overall one-sided
alpha of 0.025 for carﬁlzomib compared with control, if one interim and
ﬁnal analysis were planned. The interim analysis was scheduled to occur
after approximately 75% of the planned total OS events were reported.
An O’Brien-Fleming-type alpha-spending function determined the
monitoring boundaries for early stopping for efﬁcacy so that the overall
Type I error was less than or equal to 0.025 (one-sided). The signiﬁcance
level was adjusted per actual number of events observed using a Lan-
DeMets implementation of the O’Brien-Fleming group-sequential proce-
dure to account for multiple analyses of the primary endpoint (one interim
analysis and one ﬁnal analysis).
The assumptions for the performance of the control arm were estimated
from available information from retrospective analyses, as there were no
randomized trial results in advanced RRMM, and were further supported by
review publications that estimated a median OS of approximately 6 months
for patients with multiply relapsed MM.6,7 The assumption for the carﬁlzomib
group (median OS of approximately 8.6 months) was derived from phase II
results (median OS of 15.4 months),10 while adjusting for the more advanced
disease characteristics expected in the FOCUS study compared with previous
phase II trials.
All efﬁcacy analyses were based on the intent-to-treat population, which
consisted of all randomized patients. A stratiﬁed log-rank test was used as
primary inference to compare time to event outcomes such as OS and PFS
between the two treatment groups. One-sided P-values for OS and PFS were
from the stratiﬁed log-rank test with number of previous therapies (3 vs 4 vs
⩾5) and geographical region (Europe vs non-Europe) as stratiﬁcation factors.
The distribution of OS and PFS were summarized using the Kaplan–Meier
method per arm. Hazard ratios and corresponding 95% conﬁdence intervals
(CIs) were calculated using a stratiﬁed Cox proportional hazards model.
One-sided P-values for ORR, clinical beneﬁt rate and disease control rate
were from the Cochran–Mantel–Haenszel chi-squared test using the same
Table 1. Baseline patient and disease characteristics
Characteristic Carﬁlzomib
n= 157
Control
n= 158
Total
N= 315
Median age, years (range) 63 (32–85) 66 (43–81) 65 (32–85)
⩾ 65 years, n (%) 75 (48) 89 (56) 164 (52)
⩾ 75 years, n (%) 25 (16) 24 (15) 49 (16)
Median time since diagnosis,
years (range)
6 (2–20) 5 (2–24) 6 (2–24)
Males, n (%) 82 (52) 96 (61) 178 (57)
Region (%)
Europe 140 (89) 138 (87) 278 (88)
Race, n (%)
White 151 (96) 148 (94) 299 (95)
Black 1 (1) 1 (1) 2 (1)
Other 5 (3) 9 (6) 14 (4)
Ethnicity, n (%)
Not Hispanic or Latino 131 (83) 129 (82) 260 (83)
Not reported 4 (3) 5 (3) 9 (3)
ISS stage at initial diagnosis, n (%)
I 26 (17) 20 (13) 46 (15)
II 32 (20) 41 (26) 73 (23)
III 66 (42) 56 (35) 122 (39)
Unknown 33 (21) 41 (26) 74 (23)
Cytogenetics by FISH, n (%)
High riska 22 (14) 29 (18) 51 (16)
Standard riskb 68 (43) 76 (48) 144 (46)
Unknown risk 67 (43) 53 (34) 120 (38)
ECOG performance status, n (%)
0 49 (31) 31 (20) 80 (25)
1 78 (50) 93 (59) 171 (54)
⩾ 2 30 (19) 34 (22) 64 (20)
Serum β2-microglobulin
⩾ 5.5 mg/l, n (%)
76 (48) 82 (52) 158 (50)
Presence of bone lesions, n (%) 105 (67) 111 (70) 216 (69)
Light-chain immunoglobulin, n (%)
Kappa 93 (59) 95 (60) 188 (60)
Lambda 64 (41) 62 (39) 126 (40)
Missing 0 (0) 1 (1) 1 (o1)
Measurable disease category, n (%)
SPEP and UPEP 57 (36) 51 (32) 108 (34)
SPEP only 72 (46) 91 (58) 163 (52)
UPEP only 27 (17) 14 (9) 41 (13)
Light chain disease only 29 (18) 16 (10) 45 (14)
Median CrCl (range), ml/min 65 (16− 190) 63 (14− 207) 64 (14− 207)
CrCl o30 ml/min, n (%) 17 (11) 14 (9) 31 (10)
Baseline neuropathy grade, n (%)
0 76 (48) 81 (51) 157 (50)
1 66 (42) 56 (35) 122 (39)
⩾ 2 15 (10) 21 (13) 36 (11)
Abbreviations: CrCl, creatinine clearance; ECOG, Eastern Cooperative
Oncology Group; FISH, ﬂuorescence in situ hybridization; ISS, International
staging system; SPEP, serum protein electrophoresis; UPEP, urine protein
electrophoresis. aIncludes patients with genetic subtype t(4;14) or t(14;16)
or with deletion 17p in 60% or more of plasma cells, according to central
review of bone marrow samples obtained at study entry. bIncludes patients
without t(4;14) or t(14;16) and with deletion 17p in fewer than 60% of
plasma cells.
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randomization stratiﬁcation factors as above. Adverse events were summar-
ized using descriptive statistics. Relative dose intensity was calculated as the
actual dose intensity divided by the planned dose intensity.
This study is registered with Clinicaltrials.gov, identiﬁer NCT01302392.
Changes in methods after trial commencement
In order to adhere to guidance from the Committee for Medicinal Products
for Human Use to design a study with survival as the primary endpoint, the
primary endpoint was changed from PFS to OS. This was accompanied by
an increase in sample size from 84 to 302 in order to provide 80% power
to detect a 30% reduction in the risk of death for carﬁlzomib over control.
A regional stratiﬁcation variable was added to control for the additional
sites and countries that were added for the increased sample size. Since OS
became the primary endpoint, investigator’s assessment of response and
progression were used to determine the respective secondary efﬁcacy
endpoints, instead of the Independent Review Committee.
To align with International Myeloma Working Group guidelines, patients
with minimal response or stable disease lasting at least 8 weeks were
considered to have achieved disease control (originally 6 weeks).
An inclusion criterion that required patients to have received prior
treatment with an anthracycline was removed in order to expand study
access to patients being managed per current standard of care (which
does not support the routine use of anthracyclines). An exclusion criterion
that excluded patients with any contraindications to required concomitant
drugs or supportive treatments was added to ensure patient safety.
RESULTS
Patients and enrollment
From September 2010 to October 2012, 403 patients from 77 study
sites in Europe, Australia, New Zealand and South Korea were
screened for eligibility. A total of 315 patients were randomized into
the study and comprised the intent-to-treat population (Figure 1);
157 patients were randomized to the carﬁlzomib group and 158
were randomized to the control group. The safety population
included the 310 patients who received at least one dose of study
drug (carﬁlzomib, n=157; control, n=153).
The required number of events to conduct the ﬁnal efﬁcacy
analysis per protocol was reached on 10 July 2014 and this is the
data cutoff date used for this analysis. At data cutoff, six patients in
each of the carﬁlzomib and control groups were alive and receiving
study treatment. Median follow-up time for OS was 27.8 months
(95% CI 24.6–33.7) and 29.8 months (95% CI 24.3–33.6) in the
carﬁlzomib and control groups, respectively.
Baseline characteristics were generally well-balanced between
treatment groups, with the exception being that more patients in
the carﬁlzomib group had urine protein electrophoresis-measurable
only disease (17 vs 9%) and light-chain proteinuria (18 vs 10%) only
(Table 1). The overall study population had poor prognostic
characteristics, including International Staging System stage III and
Eastern Cooperative Oncology Group performance status ⩾2 in 39
and 20% of patients, respectively. Patients received a median of ﬁve
prior regimens of therapy (range, 3 to 17) and a median of eight
prior antimyeloma agents (range, 4 to 17). Sixty-three percent of
patients were refractory to both bortezomib and an immunomo-
dulatory agent (Table 2).
Efﬁcacy
Median treatment duration was 16.3 weeks (range, 0.3 to 138.4) in
the carﬁlzomib group and 10.7 weeks (range, 0.4 to 138.3) in the
control group. Ninety-ﬁve percent of patients in the control group
received cyclophosphamide in addition to corticosteroids. Relative
carﬁlzomib and corticosteroid dose intensity was 99.9% in both
the carﬁlzomib group and the control group.
Table 2. Prior regimens received by patients
Carﬁlzomib
n=157
Control
n=158
Total
N= 315
Number of prior regimens, n (%)
Median (range) 5 (3–15) 5 (3–17) 5 (3–17)
3 17 (11) 19 (12) 36 (11)
4 34 (22) 35 (22) 69 (22)
5 39 (25) 37 (23) 76 (24)
⩾ 6 67 (43) 67 (42) 134 (43)
Median number of unique prior antimyeloma drugs (range) 8 (5–17) 8.5 (4–14) 8 (4–17)
Patients who had prior transplant, n (%) 107 (68) 102 (65) 209 (66)
Refractory to most recent therapy, n (%) 157 (100) 157 (99) 314 (100)
Nonresponsive (oMR) 112 (71) 112 (71) 224 (71)
Progression during therapy 82 (52) 83 (53) 165 (52)
Progression within 60 days of completion of therapy 34 (22) 39 (25) 73 (23)
Prior therapy received, n (%)
Bortezomib, IMiD, alkylating agent, corticosteroid 157 (100) 158 (100) 315 (100)
Lenalidomide 132 (84) 125 (79) 257 (82)
Thalidomide 116 (74) 124 (78) 240 (76)
Pomalidomide 12 (8) 8 (5) 20 (6)
Anthracyclines 117 (75) 122 (77) 239 (76)
Received in last prior regimen, n (%)
Bortezomib 36 (23) 41 (26) 77 (24)
Bortezomib refractory in last prior regimen 36 (23) 41 (26) 77 (24)
Refractory to (in any prior regimen), n (%)
Bortezomib 103 (66) 108 (68) 211 (67)
Lenalidomide 114 (73) 112 (71) 226 (72)
Thalidomide 84 (54) 94 (59) 178 (57)
Bortezomib and IMiD 97 (62) 100 (63) 197 (63)
Alkylating agents 136 (87) 133 (84) 269 (85)
Abbreviations: IMiD, immunomodulatory agent; MR, minimal response. Patients may be counted in more than one category.
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The data met the assumptions of the statistical tests used. The
similarity of variances between treatment groups for time-to-
event outcomes was not compared as the variability of the per-
arm estimate (for example, median) depends on the number of
events, which is determined by efﬁcacy.
The HR for OS in the carﬁlzomib group compared with the control
group was 0.975 (95% CI 0.760–1.249; one-sided P=0.4172). As the
study did not meet the primary objective of carﬁlzomib superiority
over control, based on the hierarchical testing procedure to control
multiplicity, all the P-values for secondary endpoints were multi-
plicity unadjusted. Median OS was 10.2 months (95% CI 8.4–14.4)
with carﬁlzomib compared with 10.0 months (95% CI 7.7–12.0) with
control (Figure 2). OS rates at 12 and 18 months were 48 and 34%
in the carﬁlzomib group vs 42 and 30% in the control group,
respectively (Table 3).
Median PFS was 3.7 months (95% CI 2.8–4.2) in the carﬁlzomib
group compared with 3.3 months (95% CI 2.2–5.2) in the control
group (HR 1.091; 95% CI 0.843–1.410; one-sided P=0.2479) (Figure 2).
PFS rates at 12 and 18 months were 14 and 7% with carﬁlzomib vs
17 and 12% with control, respectively (Table 3).
In the carﬁlzomib group, 66.9% of patients received any
subsequent antimyeloma therapy compared with 62.0% of patients
in the control group (Supplementary Table 1). A trend was observed
of patients in the control group starting next antimyeloma therapy
sooner than in the carﬁlzomib group, which led to more patients
in the control group being censored for PFS. An exploratory analysis
of PFS that treated the receipt of next antimyeloma therapy as a PFS
event was consistent with the primary PFS analysis (Supplementary
Table 2).
The ORR was higher in the carﬁlzomib group compared with the
control group (19.1 vs 11.4%, respectively; odds ratio, 1.84; 95% CI
0.97–3.49; one-sided P= 0.0305) (Table 3). A trend was observed
for higher ORRs in the carﬁlzomib group among patients sensitive
to bortezomib, refractory to bortezomib, or refractory to both
bortezomib and an immunomodulatory agent (Supplementary
Table 3). For all patients achieving at least partial response, the
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Figure 2. Kaplan−Meier estimates of (a) OS and (b) PFS.
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median duration of response was 7.2 months (95% CI 4.6–12.0) in
the carﬁlzomib and 9.5 months (95% CI 3.7—not estimable) in the
control group. The clinical beneﬁt rate was 31.2 vs 20.9% in the
carﬁlzomib vs control groups (odds ratio, 1.70; 95% CI 1.02–2.85;
one-sided P= 0.0212), and the disease control rate was 75.8 vs
67.7%, respectively.
Safety
Incidence rates of any-grade treatment-emergent adverse events
were similar between the carﬁlzomib (98% of patients) and control
(94%) groups (Table 4). Serious AEs (carﬁlzomib group, 59%;
control group, 51%) and grade 5 AEs (carﬁlzomib group, 19%;
control group, 22%) occurred at similar rates in both groups.
Deaths due to AEs occurred in 10% of patients in the carﬁlzomib
group compared with 12% in the control group (Supplementary
Table 4). In the carﬁlzomib group, 5% of patients had their dose
reduced at least once due to an AE, 1% had their dose interrupted
due to an AE, 13% had their dose delayed due to an AE.
Discontinuation due to an AE occurred in 15% of patients in the
carﬁlzomib group and 20% of patients in the control group.
Grade ⩾ 3 AEs were similar between groups, with the exception
of acute renal failure (carﬁlzomib, 8%; control, 3%) and pneumonia
(carﬁlzomib, 6%; control, 12%) (see Table 4). Common grade ⩾ 3
nonhematologic AEs in the carﬁlzomib group were renal
failure/acute renal failure (13%), disease progression (11%), and
pneumonia (6%); common grade ⩾ 3 nonhematologic AEs in the
control group were pneumonia (12%) and disease progression
(12%). Hypertension occurred in 15% of carﬁlzomib patients and
6% of control patients.
Grouped renal failure AEs (that is, azotemia, oliguria, renal
failure, acute renal failure and renal impairment) occurred more
frequently in patients in the carﬁlzomib group compared with
the control group (24 vs 9%). Overall, these events occurred more
frequently in patients with lower CrCl at baseline (36% of all
patients with baseline CrCl o30 ml/min, 23% of all patients
with baseline CrCl of 30–50 ml/min and 12% of all patients with
baseline CrCl ⩾ 50 ml/min). Furthermore, a majority of the patients
who reported grouped acute renal failure AEs had urine protein
electrophoresis-measurable disease (carﬁlzomib group, 74%;
control group, 71%) compared with 26 and 29%, respectively, of
those without urine protein electrophoresis-measureable disease.
DISCUSSION
Patients with advanced RRMM have poor outcomes and few
treatment options as they are likely to have been exposed to
all major classes of therapeutic agents and are often refractory
to at least one agent. The FOCUS study investigated single-agent
carﬁlzomib vs low-dose corticosteroids with optional cyclopho-
sphamide in heavily pretreated patients with RRMM. The study
did not meet its primary endpoint; there was no signiﬁcant
improvement in OS for carﬁlzomib compared with control (HR for
OS 0.975; 95% CI 0.760–1.249; P= 0.4172). PFS was also similar
between the two treatment groups.
Table 3. Efﬁcacy results
Carﬁlzomib
n=157
Control
n= 158
One-sided
P-valuea
Median OS, months (range; 95% CI) 10.2 (8.4–14.4) 10.0 (7.7–12.0) 0.4172
Hazard ratio (carﬁlzomib/control) (95% CI) 0.975 (0.760–1.249)
Median PFS, years (95% CI) 3.7 (2.8–4.2) 3.3 (2.2–5.2) 0.2479
Hazard ratio (carﬁlzomib/control) (95% CI) 1.091 (0.843–1.410)
Best overall responseb, n (%)
CR 1 (1) 0 (0) NA
VGPR 5 (3) 5 (3) NA
PR 24 (15) 13 (8) NA
MR 19 (12) 15 (9) NA
SD 70 (45) 74 (47) NA
PD 26 (17) 35 (22) NA
Unable to evaluate 12 (8) 16 (10) NA
ORR, n (%) 30 (19) 18 (11) NA
95% CIc of ORR 13–26 7–17 0.0305
Median time to overall response, monthsd (range) 2.0 (0.5–11.0) 3.9 (1.0–28.0) NA
Median duration of overall response, months (95% CI) 7.2 (4.6–12.0) 9.5 (3.7–NE) NA
CBR, n (%) 49 (31) 33 (21) NA
95% CIc of CBR 24–39 15–28 0.0212
Median time to clinical beneﬁt response, monthsd (range) 1.5 (0.4–5.0) 1.9 (0.9–17.0) NA
Median duration of clinical beneﬁt response, months (95% CI) 6.4 (4.9–8.3) 8.3 (6.5–12.9) NA
DCR, n (%) 119 (76) 107 (68) NA
95% CIc of DCR 68–82 60–75 0.0514
Median duration of disease control, months (95% CI) 5.5 (3.9–6.5) 6.6 (5.4–8.8) NA
Abbreviations: CBR, clinical beneﬁt rate; CI, conﬁdence interval; CR, complete response; DCR, disease control rate; MR, minimal response; NA, not applicable;
NE, not estimable; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; sCR, stringent
complete response; SD, stable disease; VGPR, very good partial response. Overall response rate= sCR, CR, VGPR, or PR; clinical beneﬁt response rate= sCR, CR,
VGPR, PR, or MR; disease control= sCR, CR, VGPR, PR, MR, or SD. aOne-sided P-values for OS and PFS were from stratiﬁed log-rank test with number of previous
therapies (3 vs 4 vs ⩾ 5) and geographical region (Europe vs non-Europe) as stratiﬁcation factors; one-sided P-values for ORR, CBR and DCR were from
Cochran–Mantel–Haenszel chi-squared test with number of previous therapies (3 vs 4 vs⩾ 5) and geographical region (Europe vs non-Europe) as stratiﬁcation
factors; all P-values were unadjusted. bBest overall response was deﬁned as a patient’s best response during the study. A conﬁrmed MR required a minimum
duration of 8 weeks in addition to at least two consecutive assessment results of MR or higher. A conﬁrmed SD required a minimum duration of 8 weeks.
cClopper–Pearson interval. dMedians, percentiles and their 95% CIs were estimated using the Kaplan−Meier method.
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The single-agent activity of carﬁlzomib was demonstrated
by the ORR of 19.1%, which was nearly twice as high as that
noted with the control group (11.4%; one-sided P= 0.0305);
the proportion of patients achieving a minimal response or better
in the carﬁlzomib group was also higher than that in the control
group (31.2 vs 20.8%, respectively).
Incidence rates of AEs were similar between groups, with the
exception of an increase in the rate any-grade hypertension (15 vs 6%)
and grade ⩾3 grouped renal failure events in the carﬁlzomib
group (24 vs 9%). The increase in renal failure events may be possibly
explained by the inclusion of late-line patients with heavy disease
burden, with events occurring more frequently in patients with low
baseline CrCl. Notably, no increase in peripheral neuropathy was
observed with carﬁlzomib relative to control.
The study design was based on encouraging phase II results
observed with single-agent carﬁlzomib, which showed an ORR
of 24% and a median OS of 15.2 months in patients who had
received a median of ﬁve prior treatment lines (range, 1-20).10
The efﬁcacy results observed in the present study were compar-
able to those reported by Siegel et al,10 while the comparatively
shorter median OS of 10.2 months was likely due to differences
in enrollment criteria between the two studies. In the phase II
PX-171-003-A1 study, patients must have received at least two prior
regimens, had platelet counts ⩾50 000/mm3, and CrCl ⩾30ml/min;
the FOCUS study speciﬁed that patients had to have received
at least three prior regimens, have platelet counts ⩾30 000/mm3,
and CrCl ⩾ 15 ml/min.
Notably, the FOCUS study compared single-agent carﬁlzomib
against an active doublet control regimen. The addition of
dexamethasone to carﬁlzomib should be considered, particularly
in patients with suboptimal response, a strategy that had been
followed with bortezomib in the APEX study.21
Further study limitations may include the open-label nature
of the study, which may have led to more patients in the control
group initiating their next antimyeloma regimen prior to disease
progression or death (that is, censored for PFS due to start of
next therapy). It is also worth noting that treatments for RRMM are
often most effective in standard-risk patients; enrolling patients
with advanced disease, such as those with very poor Eastern
Cooperative Oncology Group performance status, renal function
and/or low platelet counts, poses a signiﬁcant hurdle for any
single-agent therapy to demonstrate clinical beneﬁt.
In conclusion, the phase III FOCUS study did not meet its primary
end point for OS, as the active control arm of corticosteroids and
optional cyclophosphamide (in which 95% of patients received
cyclophosphamide) performed better than expected and demon-
strated activity in this patient population. This active control arm
merits further evaluation in patients with RRMM. The safety proﬁle
of single-agent carﬁlzomib was generally consistent with what
has been reported previously in heavily pretreated patients with
MM, with the exception of increased renal events.10 Carﬁlzomib
combined with dexamethasone and/or other agents remains an
active treatment option for patients with advanced MM,22 based
on positive results from phase III studies in RRMM. The phase III
study ASPIRE (NCT01080391) demonstrated that the addition
of carﬁlzomib to lenalidomide-dexamethasone led to a HR for PFS
of 0.69 (95% CI, 0.57–0.83) for patients with relapsed MM,23 and the
phase III study ENDEAVOR (NCT01568866) met its primary endpoint
of improved PFS with carﬁlzomib (20/56 mg/m2; 30-min infusion)-
dexamethasone vs bortezomib-dexamethasone (HR 0.53; 95% CI
0.44–0.65) in patients with relapsed MM.24 Therefore, despite the
lack of a survival advantage observed in late-line RRMM patients,
carﬁlzomib remains an important component of anti-MM treatment
in a variety of settings.
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Table 4. Hematologic and nonhematologic adverse eventsa
Adverse event preferred
term, n (%)
Carﬁlzomib
(n= 157)
Control
(n= 153)
All
grades
Grade
⩾ 3
All
grades
Grade
⩾ 3
Any adverse event 154 (98) 118 (75) 143 (94) 109 (71)
Hematologic
Anemia 88 (56) 40 (25) 75 (49) 47 (31)
Thrombocytopenia 59 (38) 38 (24) 46 (30) 34 (22)
Neutropenia 23 (15) 12 (8) 26 (17) 19 (12)
Leukopenia 10 (6) 5 (3) 15 (10) 11 (7)
Nonhematologic
Nausea 32 (20) 2 (1) 14 (9) 2 (1)
Pyrexia 44 (28) 5 (3) 30 (20) 0 (0)
Pneumonia 12 (8) 10 (6) 20 (13) 19 (12)
Decreased platelet count 12 (8) 5 (3) 12 (8) 7 (5)
Hypercalcemia 17 (11) 6 (4) 10 (7) 7 (5)
Acute renal failure 15 (10) 12 (8) 6 (4) 5 (3)
Renal failure 10 (6) 8 (5) 3 (2) 2 (1)
Other adverse events of interest
Chest pain 5 (3) 0 (0) 9 (6) 1 (1)
Increased blood creatinine 13 (8) 3 (2) 10 (7) 1 (1)
Decreased creatinine renal
clearance
9 (6) 1 (1) 4 (3) 3 (2)
Renal impairment 11 (7) 6 (4) 5 (3) 1 (1)
Dyspnea 23 (15) 2 (1) 13 (9) 0 (0)
Cough 19 (12) 1 (1) 10 (7) 1 (1)
Hypertension 23 (15) 5 (3) 9 (6) 0 (0)
Cardiac failure 7 (5) 3 (2) 1 (1) 1 (1)
Peripheral neuropathy 7 (5) 1 (1) 6 (4) 0 (0)
aAdverse events of any grade reported in ⩾ 20% of patients in either
treatment arm and grade ⩾ 3 adverse events reported in ⩾ 5% of patients
in either treatment arm are listed. Adverse events of clinical interest are
also listed.
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